Dysfunction of γδ T cells in pediatric chronic active Epstein-Barr virus infection

Junhong Ai^{1,2}, Haijuan Xiao³, Linlin Zhang^{1,2,4}, Honghao Ma⁵, Dong Wang⁵, Dilara Dilmurat^{1,2}, Ran Wang^{1,2*} and Zhengde Xie^{1,2*}

Abstract

Chronic active Epstein-Barr virus infection (CAEBV) is a progressive and life-threatening disease characterized by persistent or recurrent EBV activation. It has been reported that, $\gamma\delta$ T cells, a type of cytotoxic lymphocyte, play a critical role in restricting EBV. However, the functional status of $\gamma\delta$ T cells in pediatric CAEBV patients has not yet been described. In this study, flow cytometry analysis was conducted to explore the cytokine production capacity of $\gamma\delta$ T cells in CAEBV patients. A diminished frequency of $\gamma\delta$ T cells and decreased expression of cytolytic molecule granzyme B were found in CAEBV patients, suggesting a dysfunction in the immune regulatory function of $\gamma\delta$ T cells in this disease.

Keywords Epstein-Barr virus, Chronic active Epstein-Barr virus infection, $\gamma\delta$ T cells, Pediatric, Dysfunction

Introduction

Epstein-Barr virus (EBV) is a ubiquitous human gamma herpesvirus, infecting over 90% of the global population. Typically, individuals acquire EBV during early childhood, and this initial infection usually manifests asymptomatic. However, delayed acquisition of EBV may lead to infectious mononucleosis (IM), characterized by acute

*Correspondence:

Ran Wang

randall@mail.ccmu.edu.cn

Zhengde Xie xiezhengde@bch.com.cn

³ Department of Infectious Diseases, Beijing Children's Hospital, Capital

Medical University, National Center for Children's Health, Beijing 100045, China

⁴ Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center

for Children's Health, Beijing 100045, China

⁵ Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China but generally benign and self-limiting symptoms [1]. In rare cases, individuals infected with EBV may develop chronic active EBV infection (CAEBV), a condition marked by persistent or recurrent IM-like symptoms for more than 3 months. CAEBV poses a significant risk to health and can potentially become life-threatening [2].

Cytotoxic lymphocytes, such as CD8⁺ T cells, NK cells, and $\gamma\delta$ T cells, play a crucial role in the immune control during EBV infection [3]. Among these, $\gamma\delta$ T cells represent a unique subset of cytotoxic lymphocytes known for their potent innate immune responses, capable of swiftly recognizing antigens in an MHC-independent manner. Studies have demonstrated an elevation the frequency of $\gamma\delta$ T cells in the peripheral blood of individuals with IM resulting from acute EBV infection [4]. Moreover, a significant portion of $\gamma\delta$ T cell in IM patients exhibit positivity for the activation marker CD38, underscoring their antiviral function during acute EBV infection [4].

 $\gamma\delta$ T cells primarily exert their function through the production of various cytokines, which facilitate cytotoxicity against target cells. Studies have indicated that during chronic viral infections, such as human immunodeficiency virus infection, chronic hepatitis B virus

BACC © The Author(s permits use, sh: original author(

© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Open Access

¹ Laboratory of Infection and Virology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

² Research Unit of Critical Infection in Children, 2019RU016, Chinese Academy of Medical Sciences, Beijing 100045, China

infection, and hepatitis C virus infection, the capacity of $\gamma\delta$ T cells to produce cytokines and execute cytotoxic functions becomes compromised [5]. However, the status of $\gamma\delta$ T cells, both in terms of frequency and functionality, in patients with CAEBV remains poorly understood due to the sustained viral activity and prolonged nature of the disease. Therefore, the aim of the study is to investigated the cytokine production capacity of $\gamma\delta$ T cells in children with CAEBV using flow cytometry analysis.

Methods

A total of 10 pediatric patients diagnosed with CAEBV (Table 1) and 18 age-matched healthy carriers (HC) of EBV (Table S1) during routine physical examinations were enrolled in this study at the Beijing Children's Hospital, Capital Medical University. Peripheral blood samples were collected from all participants.

In humans, $\gamma\delta$ T cells can be classified into V δ 1, V δ 2 and V δ 3 subtypes, with V γ 9V δ 2 T cells comprising 60–90% of peripheral blood γδ T cells [6]. Previous studies have shown that EBV-positive Daudi cells can vigorously activate Vy9V δ 2 T cells *in vitro* [7]. Therefore, in this study, peripheral blood mononuclear cells (PBMCs) from both HC and patients with CAEBV patients were isolated using density gradient centrifugation. Subsequently, these PBMCs were subjected to stimulation with Daudi cells to conduct functional assays targeting $\gamma\delta$ T cells. In brief, 5×10^5 PBMCs were cultured either alone or in the presence of Daudi cells at an effector-to-target cell ratio of 10:1. The cells were cultured for 24 h in RPMI 1640 medium with 10% fetal bovine serum and recombinant human IL-2 (25 ng/ml) (R&D Systems). For cytokine detection, GolgiStop protein transport inhibitor (BD Biosciences) was added to the cultures for the last 5 h. Flow cytometry analysis was then performed to measure the frequency of $\gamma\delta$ T cell expressing granzyme B, CD107a, perforin, IFN- γ , and TNF- α . The flow cytometry analysis strategy is illustrated in Fig. S1.

Data were analyzed using GraphPad Prism Software and are presented as mean \pm SEM. *P* values were calculated using two-tailed unpaired Student's *t* tests, with *P* values of <0.05 considered statistically significant.

Results and discussion

The results revealed a significant decrease in the percentage of $\gamma\delta$ T cells in CAEBV patients compared to HC (P < 0.05, Fig. 1A). Previous studies have indicated a negative correlation between EBV reactivation and the recovery of $\gamma\delta$ T cells following hematopoietic stem cell transplantation, underscoring the pivotal role of $\gamma\delta$ T cells in restricting EBV reactivation [8]. Hence, the observed reduction in $\gamma\delta$ T cells in CAEBV may associated with the persistent activation of EBV during the development of the disease. The functionality of $\gamma\delta$ T cells hinges on their ability to release cytotoxic effector molecules such as granzyme B, perforin, and IFN-y, which aid in eliminating infected, stressed, and transformed cells. To understand the role of $\gamma\delta$ T cells in CAEBV, we investigated their capacity to produce these cytotoxic effector molecules. Our findings, illustrated in Fig. 1B, demonstrated a significant reduction in granzyme B levels in $\gamma\delta$ T cells from CAEBV patients compared to those in HC (P < 0.05). Conversely, the expression levels of CD107a, perforin, IFN- γ and TNF- α exhibited no discernible between CAEBV patients and HC (P>0.05, Fig. 1C-F). CAEBV can be divided into T cell type and NK cell type according to the lymphocyte mainly infected by the virus. In this study, we found that in CAEBV patients, whether

Table 1 Clinical information of chronic active EBV infection (CAEBV) patients

Patient No	Gender	Age (years)	EBV load in plasma (copies/mL)	EBV load in PBMC (copies/mL)	Major lymphocyte subsets of EBV infection
CA01	М	10.08	9.44×10 ³	1.26×10 ⁶	NK
CA02	F	7.25	6.33×10^2	1.17×10 ⁷	Т
CA03	М	6.00	9.58×10 ²	7.96×10 ⁶	Not determined
CA04	F	11.08	8.05×10^{2}	2.15×10 ⁶	Т
CA05	F	13.00	9.61×10^{2}	1.08×10^{7}	Т
CA06	F	2.00	< 500	1.72×10 ⁶	Т
CA07	F	2.00	< 500	5.56×10^{6}	Т
CA08	F	5.00	< 500	1.46×10^{5}	Not determined
CA09	F	15.50	< 500	7.28×10 ³	NK
CA10	Μ	9.75	< 500	1.95×10^{6}	NK

CA CAEBV, M Male, F Female, TT cells, NK Natural killer cells




Fig. 1 Expression of cytolytic molecules in circulating $\gamma\delta$ T cells in CAEBV. PBMCs were isolated from the peripheral blood of patients with CAEBV (n = 10) and EBV healthy carriers (HC) (n = 18). The PBMCs were incubated alone or in the presence of Daudi cells and then analyzed using a BD LSRFortessa flow cytometer. **A** The proportion of $\gamma\delta$ T cells in PBMCs. **B-F** The expression levels of granzyme B, CD107a, perforin, IFN- γ , and TNF- α in $\gamma\delta$ T cells, respectively. Each point in the histogram represents a patient's data, and mean values ± SEM are also provided. ns, no statistical difference. *, P < 0.05

they have the T cell type or the NK cell type, the frequency of $\gamma\delta$ T cells decreases and granzyme B secretion is reduced.

Previously, the $\gamma\delta$ T cell function was found to be impaired in EBV-associated nasopharyngeal carcinoma, characterized by diminished IFN- γ and TNF- α production and weakened killing capacity against nasopharyngeal carcinoma cell lines in vitro [9, 10]. Although CAEBV is not been explicitly classified as malignant disease, it exhibits malignant characteristics due to clonal proliferation of EBV-infected cells and has the potential to progress to hematological malignancies, such as T-cell lymphoma [11]. The reduced expression of the cytolytic molecule granzyme B in CAEBV patients suggests an insufficient ability of $\gamma\delta$ T cell to eradicate EBV-infected clonal expansion cells, although definitive conclusions necessitate further cytotoxicity experiments. CAEBV patients may have cytokine imbalances, such as elevated levels of immunosuppressive cytokines like IL-10, which can inhibit the activation and proliferation of $\gamma\delta$ T cells [12], and prolonged chronic infection may lead to $\gamma\delta$ T cell exhaustion [13], thereby reducing granzyme B secretion [14].

 $\gamma\delta$ T cells have dual antiviral and antitumor effects. Studies have shown that adoptive immunotherapy based on $\gamma\delta$ T cells has effectively controlled EBV-induced B lymphoproliferative disease after transplantation *in vitro* and in humanized mouse models [15]. Therefore, immunotherapy based on $\gamma\delta$ T cells may be a potential effective strategy for the treatment of CAEBV in the future.

In summary, the diminished frequency of $\gamma\delta$ T cells and the decreased expression of cytolytic molecule granzyme B in CAEBV signify a dysfunction in the immune regulatory function of $\gamma\delta$ T cells in this disease.

Abbreviations

 EBV
 Epstein-Barr virus

 IM
 Infectious mononucleosis

 CAEBV
 Chronic active Epstein-Barr virus infection

 HC
 Healthy carriers

 PBMC
 Peripheral blood mononuclear cells

Acknowledgements

We thank the National Health Commission of the People's Republic of China Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College for providing us with flow cytometry platform.

Authors' contributions

JA performed the functional assays, and was a major contributor in writing the manuscript. HX, LZ and HM collected the samples and carried out the initial analysis. DW and DD participated in methodology analysis and edited the manuscript. RW and ZX conceptualized, designed the study, and revised the manuscript. All authors participated in the discussion, approved the final manuscript as submitted, and agreed to be accountable for all aspects of the work.

Funding

This work was supported by the Capital's Funds for Health Improvement and Research (2024–4-1142), Beijing Natural Science Foundation (L242117), Beijing Hospitals Authority Innovation Studio of Young Staff Funding (202328), CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-12 M-5–026), and Funding for Reform and Development of Beijing Municipal Health Commission.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All participants or their guardians provided informed consent and we confirm that all methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the Medical Ethics Committee of Beijing Children's Hospital (2019-k-357).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Received: 1 July 2024 Accepted: 2 October 2024 Published online: 12 October 2024

References

- Hu H, Deng H, Bi J, Xu Y, Li S, Xie Y, et al. Clinical characteristics and effectiveness of antiviral agents in hospitalized children with infectious mononucleosis in china: A multicenter retrospective study. Pediatr Investig. 2021;5(3):188–94.
- Ali AF, Liu J, Shang S, Chen Y. Multidisciplinary treatment of chronic active epstein-barr virus infection with multiple complications: a case report. Transl Pediatr. 2021;10(9):2402–6.
- Munz C. Cytotoxicity in epstein barr virus specific immune control. Curr Opin Virol. 2021;46:1–8.
- Long HM, Meckiff BJ, Taylor GS. The t-cell response to epstein-barr virusnew tricks from an old dog. Front Immunol. 2019;10:2193.
- Hou W, Wu X. Diverse functions of gammadelta t cells in the progression of hepatitis b virus and hepatitis c virus infection. Front Immunol. 2020;11:619872.
- Mensurado S, Blanco-Dominguez R, Silva-Santos B. The emerging roles of gammadelta t cells in cancer immunotherapy. Nat Rev Clin Oncol. 2023;20(3):178–91.
- Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, et al. Two alternate strategies for innate immunity to epstein-barr virus: One using nk cells and the other nk cells and gammadelta t cells. J Exp Med. 2017;214(6):1827–41.
- Liu J, Bian Z, Wang X, Xu LP, Fu Q, Wang C, et al. Inverse correlation of vdelta2(+) t-cell recovery with ebv reactivation after haematopoietic stem cell transplantation. Br J Haematol. 2018;180(2):276–85.
- 9. Zheng BJ, Ng SP, Chua DT, Sham JS, Kwong DL, Lam CK, Ng MH. Peripheral gamma delta t-cell deficit in nasopharyngeal carcinoma. Int J Cancer. 2002;99(2):213–7.

- Puan KJ, Low JS, Tan TW, Wee JT, Tan EH, Fong KW, et al. Phenotypic and functional alterations of vgamma2vdelta2 t cell subsets in patients with active nasopharyngeal carcinoma. Cancer Immunol Immunother. 2009;58(7):1095–107.
- Kawada JI, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, et al. Updated guidelines for chronic active epstein-barr virus disease. Int J Hematol. 2023;118(5):568–76.
- 12. Liu L, Wang Y, Wang W, Ying W, Sun B, Wang X, Sun J. Increased expression of the tlr7/9 signaling pathways in chronic active ebv infection. Front Pediatr. 2022;10:1091571.
- Chen D, Guo Y, Jiang J, Wu P, Zhang T, Wei Q, Huang J, Wu D. Gammadelta t cell exhaustion: Opportunities for intervention. J Leukoc Biol. 2022;112(6):1669–76.
- 14. Ma R, Yuan D, Guo Y, Yan R, Li K. Immune effects of gammadelta t cells in colorectal cancer: A review. Front Immunol. 2020;11:1600.
- Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y, et al. Targeted activation of human vgamma9vdelta2-t cells controls epstein-barr virus-induced b cell lymphoproliferative disease. Cancer Cell. 2014;26(4):565–76.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.